CD200 expression in hematopoietic neoplasms: Beyond a marker for diagnosis of B-cell neoplasms

• Published in: Critical reviews in oncology/hematology 2021-11, Vol.167, p.103509-103509, Article 103509
• Main Authors: Staub, Renata B., Marcondes, Natália A., Rotta, Liane N.
• Format: Article
• Language: English
• Subjects: B-Lymphocytes; CD200; Hematologic Neoplasms; Hematopoietic neoplasms; Humans; Immune response; Lymphoma, B-Cell; Multiple Myeloma; OX-2; Prognosis
• ISSN: 1040-8428; 1879-0461
• DOI: 10.1016/j.critrevonc.2021.103509

[Display omitted] •CD200 appears to be involved in imune evasion of malignant cells.•CD200 expression decreases overall survival in Acute Myeloid Leukemia patients, worsening the prognosis.•CD200 expression leads to more advanced stages of diagnosis in Plasma Cell Myeloma, worsening the event free survival. CD200 (OX-2) is expressed in myeloid cells, B cells, subsets of T cells and on other normal and neoplastic non-hematopoietic cells. It interacts with CD200R and has a suppressive effect on T cells immune mediated response. We aimed to review CD200 expression and its role in the immune evasion of non-B cell hematopoietic neoplasms. In acute myeloid leukemia, CD200 seems to be related to the worst outcome, even in diseases of good prognosis, possibly due to an immunosuppressive effect. In plasma cell myeloma studies, while some have associated CD200 expression with worst prognosis possibly due to its suppressive effect on monocyte and T cell-mediated immune response, in others CD200 appeared to be a marker of a better outcome, or even showed no impact in event-free survival (EFS). Few studies have evaluated CD200 expression in T cell neoplasms; however, it appears to be a good immunophenotypic marker for angioimmunoblastic T cell lymphoma. In conclusion, CD200 appears to be involved in the immune evasion of malignant cells, which could affect the survival of these patients.